COMPARISON OF CHANGE IN CENTRAL CORNEAL THICKNESS IN PATIENTS OF PRIMARY OPEN ANGLE GLAUCOMA ON PROSTAGLANDINS MONOTHERAPY, BETA BLOCKERS MONOTHERAPY AND CARBONIC ANHYDRASE INHIBITOR-BETA BLOCKER COMBINATION THERAPY
Main Article Content
Keywords
Primary open angle glaucoma, Central corneal thickness, prostaglandins monotherapy, beta blockers monotherapy, carbonic anhydrase inhibitor
Abstract
BACKGROUND: The most prevalent type of glaucoma worldwide is the primary open angle glaucoma (POAG). It features progressive retinal ganglionic cell axons’ loss causing peripheral visual field loss initially and ultimately leading to irreversible blindness if left unmanaged. IOP is the only modifiable factor with proven effect in stopping glaucomatous damage.
OBJECTIVE: To compare the change in central corneal thickness (CCT) in patients of primary open angle glaucoma (POAG) on Prostaglandins monotherapy, beta blockers monotherapy and Carbonic Anhydrase Inhibitor (CAI) - Beta Blocker
combination therapy.
MATERIALS AND METHODS
This quasi-experimental study was carried out at Institute of Ophthalmology Unit III, KEMU/Mayo Hospital, Lahore. The study was completed in 1 year after the approval of synopsis. Patients were started on prostaglandins monotherapy (latanoprost), beta blockers monotherapy (betagan) or CAI-beta blockers combination therapy (Co-dorzal) as per the need; placed in groups A, B and C respectively. CCT was measured before the start of therapy with the use of pachymeter.
RESULTS: The results showed the mean age of all patients to be 51.65 ± 9.62 years with minimum and maximum age as 40 and 85 years. In this study there were 65(45.1%) male and 79(54.9%) female cases. At baseline, the mean CCT of the right side was 540.12 ± 4.10, 539.25 ± 3.35 and 538.98 ± 3.17 in the groups A, B and C respectively with no significant difference. On the left side, the mean CCT was 539.75 ± 3.43, 538.71 ± 2.47 and 538.98 ± 3.09 for groups A, B and C respectively with no significant difference.
CONCLUSION: It is concluded that the mean change in central corneal thickness and IOP was statistically higher in group A ( prostaglandins monotherapy) patients as compared to group-B (beta-blockers) and group-C (beta-blockers and carbonic anhydrase inhibitors combination therapy) in primary open angle glaucoma patients. Hence in future the effect of drugs must be borne in mind when measuring IOP and the measurement be adjusted with repeated central corneal thickness measurements.
References
2. Martin E, Patrianakos T, Giovingo M. Medication induced glaucoma. Dis Mon.2017;63(2):54-7.
3. Bourne RR, Taylor HR, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Number of People Blind or Visually Impaired by Glaucoma Worldwide and in World Regions 1990 - 2010: A Meta-Analysis. PLoS One. 2016;11(10):1-16.
4. Chan EW, Li X, Tham YC, Liao J, Wong TY, Aung T, et al. Glaucoma in Asia: regional prevalence variations and future projections. Br J Ophthalmol.2016;100(1):78-85.
5. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-90.
6. Palmer JJ, Chinanayi F, Gilbert A, Pillay D, Fox S, Jaggernath J, et al. Trends and implications for achieving VISION 2020 human resources for eye health targets in 16 countries of sub-Saharan Africa by the year 2020. Hum Resour Health.2014;12(45):1478-4491.
7. Carvalho CG, Procianoy RS, Neto EC, Silveira RC. Preterm Neonates with Respiratory Distress Syndrome: Ventilator-Induced Lung Injury and Oxidative Stress.J Immunol Res. 2018;2018:6963754.
8. Jacobs DS. Open-angle glaucoma: Treatment,[Updated 2018;cited 2018].Available from:URL https://www.uptodate.com/contents/open-angle-glaucoma-treatment. UpToDate com.2013.
9. Khawaja A, Kozak A, Jindal AP, Salim S. Primary open-angle glaucoma. Eyewiki[internet]. [updated 2017;cited 2018]. Avaialablefrom:URL http://eyewiki.aao.org/Primary_Open-Angle_Glaucoma. 2017.
10. Schmid K, Irak I. Primary Open-Angle Glaucoma (POAG) Treatment & Management. Medscape.[updated 2018;cited 2018]; Available from: URL https:// emedicine. medscape. Com /article/1206147-treatment#showall. 2009.
11. Stefan C, Dumitrica DM, Tebeanu E, Nae I, Sapundgieva A, Dragomir L. [Prostaglandin analogues and central corneal thickness]. Oftalmologia.2007;51(4):95-9.
12. Viestenz A, Martus P, Schlötzer-Schrehardt U, Langenbucher A, Mardin CY. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes]. Klin Monbl Augenheilkd. 2004;221(9):753-6.
13. Grueb M, Rohrbach JM. Effect of timolol on central corneal thickness. Eur J Ophthalmol. 2013;23(6):784-8.
14. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA. Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology. 2008;115(9):1550-6.
15. Kocabeyoglu S, Mocan MC, Irkec M. Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues. Indian J Ophthalmol.2015;63(1):15-9.
16. Panos GD, Konstantinidis A, Mendrinos E, Kozobolis V, Perente I, Gatzioufas Z. Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma. Curr Eye Res. 2013;38(9):977-82.
17. Maruyama Y, Mori K, Ikeda Y, Ueno M, Kinoshita S. Effects of long-term topical prostaglandin therapy on central corneal thickness. J Ocul Pharmacol Ther. 2014;30(5):440-4.
18. You JY, Cho BJ. Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma. J Ocul Pharmacol Ther. 2013;29(3):335-8.
19. Viswanathan D, Goldberg I, Graham SL. Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clin Exp Ophthalmol. 2013;41(4):348-54.
20. Singh AK. Effect of Latanoprost Eye Drops on Central Corneal Thickness in North Indian Population. nternational Journal of Science and Research (IJSR). 2016;5(7):243-45.
21. Bafa M, Georgopoulos G, Mihas C, Stavrakas P, Papaconstantinou D, Vergados I. The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes. Acta Ophthalmol. 2011;89(5):448-51.
22. Tsikripis P, Papaconstantinou D, Koutsandrea C, Apostolopoulos M, Georgalas I. The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes. Drug Des Devel Ther. 2013;7:1149-56.
23. Aghaian E, Choe JE, Lin S, Stamper RL. Central corneal thickness of Caucasians, Chinese, Hispanics, Filipinos, African Americans, and Japanese in a glaucoma clinic. Ophthalmology. 2004;111(12):2211-9.
24. Wiggs JL, Pasquale LR. Genetics of glaucoma. Hum Mol Genet. 2017;26(R1):R21-R7.
25. Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86-93.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sara Ashraf
Senior Registrar, Al-Aleem Medical College,Lahore, Pakistan
Ramsha Jehangir
Consultant Ophthalmologist, VR Fellow, Lahore General Hospital, Lahore, Pakistan.
Faraz Munir
Senior Registrar, Department of Ophthalmology, Akhter Saeed Teaching Hospital,Lahore,Pakistan.
Abeer Fatima
Consultant ophthalmologist Khizar Eye Center
Hira Shuja Khokhar
Senior Registrar, Department of Ophthalmology, Gujranwala Medical College Teaching Hospital, Gujranwala, Pakistan
Syed Muhammad Jahangir
Consultant Ophthalmologist, Eye Site Clinic,Lahore, Pakistan
Ayesha Naeem
Doctor of Pharmacy, Forman Christian College, University, Lahore